FDA-approved Setmelanotide Shows Promise in More Genetic Obesity Disorders

FDA-approved Setmelanotide Shows Promise in More Genetic Obesity Disorders

284640

FDA-approved Setmelanotide Shows Promise in More Genetic Obesity Disorders

Three months of treatment with setmelanotide, an approved therapy for genetic obesity disorders, led to clinically meaningful body weight loss in adolescents and adults with additional diseases linked to the melanocortin-4 receptor (MC4R) pathway, data show. These interim data, from a Phase 2 basket trial, highlight setmelanotide’s potential for treating so-called heterozygous (HET) obesity — caused by mutations in only one copy of the POMC, PCSK1, or LEPR genes — as well as SRC1 deficiency,…

You must be logged in to read/download the full post.